Introduction
============

Gastric cancer (GC) is a common malignant tumor of the digestive system that originates in the gastric mucosal epithelium. GC is a frequently diagnosed type of cancer and is an important leading cause of cancer-related mortality according to the cancer statistics of 2019 ([@b1-ijo-57-01-0122]). Currently, the majority of patients with early-stage GC have a relatively long-term survival time after selecting surgery as a principal treatment option ([@b2-ijo-57-01-0122]-[@b4-ijo-57-01-0122]). In recent years, a program combining immunotherapy, molecular targeted therapy and neoadjuvant chemoradiotherapy has been shown to be a promising treatment method for GC ([@b5-ijo-57-01-0122]-[@b9-ijo-57-01-0122]). However, the molecular mechanisms associated with the occurrence and progression of GC remain unclear. Therefore, the exploration of cancer-related genes and specific molecular targets for the effective treatment of GC is imperative.

SAC3 domain containing 1 (SAC3D1) is a protein-coding gene located on chromosome 11 and is widely found in the cytoplasm, cytoskeleton, microtubule tissue center, centrosome and spindle ([@b10-ijo-57-01-0122]). SAC3D1 has been reported to be abnormally expressed in multiple types of cancer and may be associated with the occurrence or progression of numerous types of cancer. A previous study reported that SAC3D1 may serve as a prognostic biomarker in hepatocellular carcinoma by combining the data of Gene Expression Omnibus (GEO), The Cancer Genome Atlas and International Cancer Genome Consortium ([@b11-ijo-57-01-0122]). The prognostic value of SAC3D1 has also been demonstrated in colon cancer ([@b12-ijo-57-01-0122]). You *et al* reported that SAC3D1 was associated with SLC2A5-inhibited adjacent lung adenocarcinoma cytoplasmic pro-B cell progression ([@b13-ijo-57-01-0122]). However, the role and molecular mechanisms of action of SAC3D1 in GC have not yet been reported. According to a preliminary calculation with TCGA RNA-seq data, SAC3D1 was found to be significantly abnormally expressed in GC. Thus, it was speculated that SAC3D1 may play a pivotal clinical role in GC.

In the present study, GC microarray data and RNA-seq data were integrated to assess the mRNA expression of SAC3D1 in GC, and an in-house immunohistochemistry (IHC) was performed to further validate the protein expression level of SAC3D1. The co-expressed genes of SAC3D1 in GC were also collected and the possible molecule molecular mechanisms of action of SAC3D1 were analyzed by bioinformatics methods ([Fig. 1](#f1-ijo-57-01-0122){ref-type="fig"}).

Materials and methods
=====================

Data sources and processing
---------------------------

GC microarray and RNA-seq data were screened from the Sequence Read Archive (SRA; <https://www.ncbi.nlm.nih.gov/sra>) ([@b14-ijo-57-01-0122]), Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) ([@b15-ijo-57-01-0122]), ArrayExpress(<http://www.ebi.ac.uk/arrayexpress/>) ([@b16-ijo-57-01-0122]) and Oncomine (<https://www.oncomine.org/resource/main.html>) ([@b17-ijo-57-01-0122]) databases with the following keywords: (\'gastric\' OR \'stomach\' OR \'gastrointestinal\') AND (\'cancer\' OR \'carcinoma\' OR \'tumor\' OR \'adenocarcinoma\'). The inclusion criteria were as follows: First, the experimental group and the control group should be human GC samples and healthy samples, respectively. Second, lymph node metastasis and distant metastasis tissues were also included in the present study. Third, the calculated mRNA expression data should be provided by all included datasets. The information of included GC microarray and RNA-seq data is presented in [Table I](#tI-ijo-57-01-0122){ref-type="table"}. Besides, microarray and RNA-seq data with prognostic data were screened separately for prognostic-related analysis. The mRNA expression matrix data of each dataset were downloaded, and the mRNA expression data of SAC3D1 were extracted. The SAC3D1 expression data underwent a log2 transformation and were divided into cancer groups and normal groups. The GC RNA seq data of the TCGA database were downloaded from UCSC Xena (<https://xena.ucsc.edu/>), which included sequencing data of 373 GC and 32 normal tissues. The data were processed as microarray data. The GC-related clinical parameters, including sex, grade, age, TNM stage and survival data, were also acquired from UCSC Xena.

In-house IHC
------------

The tissue array that included 179 cases of GC tissues and 147 normal tissues was purchased from Pantomics, Inc. and some clinical information for each sample, such as age, sex, tumor pathological grade and clinical stage, were also provided. In the IHC analysis, SAC3D1 was detected with anti-SAC3D1 antibody (at a 1/500 dilution; cat. no. ab122809, Abcam\'s RabMAb technology). The SAC3D1 expression intensity for each sample was evaluated based on the score, and the score was generated from the product of the proportion of stained cells among all cells (0, \<5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; 4, \>75%) and the staining degree of the positive cells (0, no staining; 1, light yellow or yellow; 2, brown; 3, dark brown) ([@b18-ijo-57-01-0122]). Images were captured using an optical microscope (Motic China Group Co., Ltd.). Moreover, to improve the accuracy of results, Image-Pro Plus version 6.0 software (Media Cybernetics, Inc.) was also used to evaluate the area and density of the dyed region and the integrated optical density (IOD) value of the IHC section. The mean densitometry of the digital image (magnification, ×400) was regarded as representative SAC3D1 staining intensity (indicating the relative SAC3D1 expression level). The IOD values of the tissue areas from 179 cases of gastric cancer tissues and 147 normal tissues randomly selected fields were calculated counted in a blinded manner and subjected to statistical analysis.

Mutations of the SAC3D1 in GC
-----------------------------

Genetic alterations of SAC3D1 in GC were investigated based on high throughput data in cBio-Portal for Cancer Genomics (cBioportal) (<http://cBioportal.org>) and Catalogue Of Somatic Mutations In Cancer (COSMIC) (<https://cancer.sanger.ac.uk/cosmic>), including missense mutation, truncating mutation, deep deletion, and amplification.

Acquisition of co-expressed genes of SAC3D1 in GC
-------------------------------------------------

The co-expressed genes of SAC3D1 were obtained from the Multi Experiment Matrix (<https://biit.cs.ut.ee/mem/index.cgi>) ([@b19-ijo-57-01-0122]) and COXPRESdb (<http://coxpresdb.jp>) ([@b20-ijo-57-01-0122]). In the Multi Experiment Matrix, P\<0.05 was regarded as statistically significant. In COXPRESdb, 2000 was set as the upper limit. In addition, GC-related differentially expressed genes were calculated with the edgeR package based on TCGA and GTEx data, and a log (fold change) equal to 1 and P\<0.05 was defined as including condition. The overlapped genes of three parts were considered co-expressed genes of SAC3D1 in GC.

Enrichment and protein-protein interaction (PPI) analysis
---------------------------------------------------------

The genes co-expressed with SAC3D1 were submitted to DAVID (<https://david.ncifcrf.gov/>) ([@b21-ijo-57-01-0122]) for an enrichment analysis, including gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. STRING (<https://string-db.org/>) ([@b22-ijo-57-01-0122]) was utilized to construct a PPI network, and based on the degree of nodes, hub co-expressed genes of SAC3D1 were identified.

Validation of hub co-expressed genes
------------------------------------

The expression of hub co-expressed genes was further validated at the mRNA level based on the microarray and RNA-seq data via a meta-analysis and the protein expression levels of hub co-expressed genes were verified in Human Protein Atlas (HPA) (<https://www.proteinatlas.org/>) ([@b23-ijo-57-01-0122]). The sensitivity and specificity of hub co-expressed genes on differentiating GC tissues and normal tissues were also calculated. Besides, genetic alterations of the hub co-expressed genes in GC were also investigated in cBioportal. A prognosis related meta-analysis was also conducted to assess the prognosis value of hub co-expressed gene, respectively. Moreover, the expression relationship between SAC3D1 and hub co-expressed genes was presented by correlation analysis.

Statistical analysis
--------------------

Independent and paired sample t-tests were performed in SPSS 19.0 to calculate and evaluate the expression level of SAC3D1 in GC tissues and normal tissues based on the GC microarray data, RNA seq data and IHC data. Stata 12.0 was used to perform a continuous variable meta-analysis and calculate the value of SMD. One-way analysis of variance was used in the present study to compare the differences in the mean of three or more sets of data. Bonferroni and Tamhane\'s T2 were used as post hoc tests for equal variance assumed and equal variance not assumed, respectively. In addition, the sensitivity and specificity of SAC3D1 on differentiating GC tissues and normal tissues were evaluated by drawing ROC curves in GraphPad Prism5 based on microarray data, RNA seq data, and IHC data. Stata 12.0 was also used to integrate the results of each ROC with a summary ROC. Finally, a Spearman\'s correlation analysis was used to examine the relationship between the expression of SAC3D1 and core co-expressed genes.

Results
=======

Expression and clinical value of SAC3D1 in GC based on chips and RNA-seq data
-----------------------------------------------------------------------------

First, a total of 18 eligible GEO chips and a section of TCGA sequencing data were collected, including 1,241 gastric cancer samples and 452 normal samples, from which the expression data of SAC3D1 was extracted. The expression of SAC3D1 in each chip or section of TCGA sequencing data was clarified through independent or paired sample t-tests. For the GEO chips, 5 chips (GSE103236, GSE29272, GSE13911, GSE112369 and GSE26899) exhibited a significantly upregulated trend of SAC3D1 in GC. For the TCGA sequencing data, SAC3D1 was found to be upregulated in 373 gastric cancer tissues (17.3966±0.78827) compared to 32 normal tissues (16.8133±0.34279, P\<0.001) ([Table I](#tI-ijo-57-01-0122){ref-type="table"} and [Fig. 2](#f2-ijo-57-01-0122){ref-type="fig"}). To further improve the accuracy of the results, the results of t-tests based on 18 eligible GEO chips and a section of TCGA sequencing data were integrated by a continuous variable meta-analysis. The results indicated that SAC3D1 was clearly upregulated in GC tissues with the SMD of the random effect model being 0.45 (0.12, 0.79), and the funnel plot indicated that there was no publication bias ([Fig. 3A and B](#f3-ijo-57-01-0122){ref-type="fig"}). The ROC of all chips and RNA-seq data was calculated ([Table II](#tII-ijo-57-01-0122){ref-type="table"} and [Fig. 4](#f4-ijo-57-01-0122){ref-type="fig"}), and the AUC of sROC was 0.71 (0.67, 0.75), with pooled sensitivity and specificity being 0.68 (0.61, 0.74) and 0.66 (0.60, 0.72) ([Fig. 5A and B](#f5-ijo-57-01-0122){ref-type="fig"}). The prognosis-related meta-analysis indicated that the overexpression of SAC3D1 was closely associated with the poor prognosis of patients with GC \[HR, 2.83 (2.25, 3.57); P\<0.001\] ([Fig. 3E](#f3-ijo-57-01-0122){ref-type="fig"}).

Expression and clinical value of SAC3D1 in GC based on chips, RNA seq data and IHC data
---------------------------------------------------------------------------------------

The protein expression of SAC3D1 was clearly high expressed in 179 GC tissues compared with 147 paracancerous tissues ([Fig. 2T](#f2-ijo-57-01-0122){ref-type="fig"}). The results of t-tests based on IHC data, 18 eligible GEO chips and a section of TCGA RNA-seq data were also merged by a meta-analysis. An upregulation of SAC3D1 was finally determined with the SMD of the random effect model being 0.59 (0.11, 1.07), and a corresponding funnel plot indicated that there was no publication bias ([Fig. 3C and D](#f3-ijo-57-01-0122){ref-type="fig"}). After constructing the sROC curve based on the IHC data, 18 eligible GEO chips and a section of TCGA RNA-seq data, it was found that SAC3D1 has a certain potential to be identified as a molecular indicator to identify GC tissues and normal tissues, and the sensitivity and specificity was 0.72 (0.63, 0.79) and 0.68 (0.62, 0.74), respectively ([Fig. 5C and D](#f5-ijo-57-01-0122){ref-type="fig"}). Moreover, it was found that the positive ratio of SAC3D1 staining was comparable with the original methods using Image-Pro Plus version 6.0 software ([Fig. S1](#SD1-ijo-57-01-122){ref-type="supplementary-material"} and [Table SI](#SD1-ijo-57-01-122){ref-type="supplementary-material"}).

Association of SAC3D1 expression with clinical parameters
---------------------------------------------------------

According to the IHC data, the upregulation of SAC3D1 was statistically associated with the histological grade, clinical stage, T stage and N stage of GC. In a more advanced stage of the disease, or histological grade, the protein expression intensity of SAC3D1 was stronger than that in low-stage or grade. Thus, it was speculated that SAC3D1 may be involved in the development and progression of GC ([Fig. 6](#f6-ijo-57-01-0122){ref-type="fig"} and [Table III](#tIII-ijo-57-01-0122){ref-type="table"}). In addition, the association between SAC3D1 and some clinical parameters was also calculated using the TCGA data, and the results indicated that the expression of SAC3D1 was associated with the N stage ([Table IV](#tIV-ijo-57-01-0122){ref-type="table"}, F=7.596, P\<0.001).

Genetic alterations of the SAC3D1 in GC
---------------------------------------

From the online analysis of cBioPortal and COSMIC, it was found that SAC3D1 has a mutation in GC, although the genetic alteration rate was relatively low. Therefore, it was hypothesized that the role of highly expressed SAC3D1 in the development of GC may not be mutated, amplification-mediated ([Fig. 7](#f7-ijo-57-01-0122){ref-type="fig"}).

Enrichment and PPI analysis of co-expressed gene of SAC3D1
----------------------------------------------------------

A total of 8,364 and 2,000 co-expressed genes of SAC3D1 were obtained in the Multi Experiment Matrix (<https://biit.cs.ut.ee/mem/index.cgi>) and COXPRESdb, respectively. In addition, 4,640 GC-related differentially expressed genes were acquired after TCGA and GTEx data calculations. Finally, 410 overlapping genes of 3 parts were considered co-expressed genes of SAC3D1 in GC ([Fig. 8A](#f8-ijo-57-01-0122){ref-type="fig"}). The GO-enriched analysis indicated that SAC3D1 and co-expressed genes were mainly enriched in mitotic sister chromatid segregation, nuclear chromosome and ATP binding ([Table V](#tV-ijo-57-01-0122){ref-type="table"} and [Fig. 8C-F](#f8-ijo-57-01-0122){ref-type="fig"}). In the KEGG pathway analysis, the SAC3D1 and co-expressed genes were mainly enriched in DNA replication and the cell cycle ([Table VI](#tVI-ijo-57-01-0122){ref-type="table"} and [Fig. 8B and G](#f8-ijo-57-01-0122){ref-type="fig"}). The PPI network indicated that CDK1, CCNB1, CCNB2 and CDC20 were the hub co-expressed genes of SAC3D1 in GC ([Fig. 9A and B](#f9-ijo-57-01-0122){ref-type="fig"}).

Validation of hub co-expressed genes based on TCGA and HPA
----------------------------------------------------------

Various types of mutations of the 4 hub co-expressed genes (CDK1, CCNB1, CCNB2 and CDC20) were observed in GC ([Fig. 9C](#f9-ijo-57-01-0122){ref-type="fig"}). CDK1, CCNB1, CCNB2 and CDC20 were evidently highly expressed in GC based on the microarray and RNA-seq data mRNA expression data ([Fig. 10A-D](#f10-ijo-57-01-0122){ref-type="fig"}) and CDK1, CCNB1, CCNB2 and CDC20 may also serve as biomarkers differentiating GC tissues and normal tissues with a relative high sensitivity and specificity ([Fig. 10E-H](#f10-ijo-57-01-0122){ref-type="fig"}). The high expression trends of these 4 genes were also observed in protein expression data based on the HPA database ([Fig. 11](#f11-ijo-57-01-0122){ref-type="fig"}). These genes were risk factors affecting the prognosis of gastric cancer ([Fig. 12A-D](#f12-ijo-57-01-0122){ref-type="fig"}). Moreover, Spearman\'s correlation analysis indicated that there were significant positive correlations between SAC3D1 and these core co-expressed genes ([Fig. 12E-H](#f12-ijo-57-01-0122){ref-type="fig"}).

Discussion
==========

In the present study, the expression of SAC3D1 in GC was determined by integrated and thoroughly re-processed 18 GEO chips, TCGA RNA-seq data and IHC data, which included 1,420 GC tissues and 599 normal tissues. Notably, both SAC3D1 mRNA and protein levels were observed to be upregulated in GC tissues. The overexpression SAC3D1 was associated with the histological grade, clinical stage, T stage and N stage of GC, revealing that SAC3D1 may be involved in the development and progression of GC. Enrichment analysis revealed that SAC3D1 and 4 other SAC3D1-related genes (CDK1, CCNB1, CCNB2 and CDC20) are important for GC development via the cell cycle pathway.

Numerous studies have reported the overexpression of SAC3D1 in several types of cancer, including hepatocellular carcinoma ([@b11-ijo-57-01-0122]), colon cancer ([@b12-ijo-57-01-0122]) and lung adenocarcinoma ([@b13-ijo-57-01-0122]). Recent studies have assessed the prognostic value of SAC3D1 using GEO, the Cancer Genome Atlas and International Cancer Genome Consortium and suggested that SAC3D1 may be a credible prognosis-related biomarker for hepatocellular carcinoma ([@b11-ijo-57-01-0122]). In colon cancer, the upregulation of SAC3D1 was confirmed by a quantitative PCR ([@b12-ijo-57-01-0122]). In lung adenocarcinoma, SAC3D1 may be involved in the inhibition of cytoplasmic pro-B cell developmental mechanisms in paracancerous tissue of lung adenocarcinoma by low glucose transporter SLC2A5 ([@b13-ijo-57-01-0122]). However, to the best of our knowledge, no studies to date have clarified the expression of SAC3D1 in GC, and the expression of SAC3D1 in other cancers was only validated based on small sample sizes or a single method, which may decrease the reliability of their conclusion. Particularly, no research or clinical trials have specifically been done attempting to reveal the molecular mechanisms of SAC3D1 in cancers, including GC.

To explore the possible molecular mechanisms of actoin of SAC3D1 in GC, an enrichment analysis was performed for SAC3D1 and its co-expressed genes. The results indicated that SAC3D1 and co-expressed genes were positively associated with the cell cycle. Additionally, numerous studies have demonstrated that the cell cycle pathway plays an important role in cancer cells. Cao *et al* reported that the regulatory mechanism of BIRC5 and co-expressed genes in lung carcinoma may be closely related to the cell cycle ([@b24-ijo-57-01-0122]). Liu *et al* reported that upregulated differentially expressed genes participated in regulating breast cancer cells by the cell cycle pathway ([@b25-ijo-57-01-0122]). Moreover, Qiu *et al* revealed that the modules and central genes associated with the development of breast cancer were significantly enriched in the cell cycle pathway ([@b26-ijo-57-01-0122]). Feng *et al* investigated poor prognosis-related genes of ovarian cancer by bioinformatics analysis and found that these genes were mainly enriched in the cell cycle pathway ([@b27-ijo-57-01-0122]). It has also been reported that the cell cycle pathway is the key signaling pathway for 8 target therapy of neuroblastomas ([@b28-ijo-57-01-0122]). Zhang *et al* reported that LncRNA CASC11 promoted the proliferation, migration, and invasion of GC cells *in vitro* via the cell cycle pathway ([@b29-ijo-57-01-0122]). A number of studies have documented that the cell cycle pathway may play a role in the regulation of multiple types of cancer, including GC and enrichment analysis revealed that SAC3D1 and its co-expressed genes were involved in the cell cycle pathway. This prompted the hypothesis that SAC3D1 may be related to the occurrence and progression of GC. A total of 4 genes (CDK1, CCNB1, CCNB2 and CDC20) were determined as the core co-expressed genes of SAC3D1 in GC, and it was speculated that SAC3D1 may cooperate with these genes to promote the progression of GC. Further *in vitro* experimental analyses are still required to verify the findings of the present study, such as SAC3D1 overexpression or interference.

CDK1 is a cell cycle-related gene that can be regulated by KIAA0101 and is involved in the occurrence and development of GC ([@b30-ijo-57-01-0122]). CDK1 can also be regulated by LncRNA CASC11 and then participate in the proliferation, migration, and invasion of GC cells ([@b29-ijo-57-01-0122]). Guo *et al* demonstrated that rhCNB may decrease the expression of cell cycle B1 and CDK1 proteins and participate in the mechanism of cell cycle arrest ([@b31-ijo-57-01-0122]). CCNB1 is a cell cycle-related gene that can be regulated by ISL1 to promote the proliferation and tumor growth of GC cells ([@b32-ijo-57-01-0122]). CCNB1 can be used as a biomarker to monitor prognosis and hormone therapy in ER breast cancer ([@b33-ijo-57-01-0122]). It has also been reported that the overexpression of CCNB1 induced by chk1 can promote the proliferation and tumor growth of human colorectal cancer cells and inhibit the induction of apoptosis in some colorectal cancer cells ([@b34-ijo-57-01-0122]). CCNB1 could also activate FOXM1 and promote the proliferation of human hepatocel-lular carcinoma cells ([@b35-ijo-57-01-0122]). CCNB1 may serve as a promising diagnostic tool for determining the high risk of recurrence in patients with non-myenteric invasive bladder cancer ([@b36-ijo-57-01-0122]). CCNB2 is a cell cycle-related gene that can be regulated by ISL1 to promote the proliferation and tumor growth of GC cells ([@b32-ijo-57-01-0122]). In addition, the overexpression of CCNB2 protein is related to the clinical progress and poor prognosis of non-small cell lung cancer, and over-expressed CCNB2 is a biomarker of poor prognosis in Chinese patients with non-small cell lung cancer ([@b37-ijo-57-01-0122]). The increased expression of the cell cycle-related gene CCNB2 is related to the advanced growth of prostate cancer cell subsets ([@b38-ijo-57-01-0122]). Kim *et al* reported that the expression of CDC20 in early GC was significantly higher than that in normal mucous membranes ([@b39-ijo-57-01-0122]). The upregulation of CDC20 was associated with invasive progress and poor prognosis in GC, and it was identified as an independent marker for predicting clinical outcomes in patients with GC ([@b40-ijo-57-01-0122]). It has also been reported that CDC20 expression can be used as a biomarker for tumor prognosis or as a therapeutic target for other human cancers ([@b41-ijo-57-01-0122]). In addition, CDC20 can mediate docetaxel resistance to castrated prostate cancer ([@b42-ijo-57-01-0122]).

Microarray and RNA-seq data were combined to evaluate the prognostic value of 4 hub co-expressed genes via a prognostic-related meta-analysis. It was found that the upregulation of these genes were closely related to the poor prognosis of patients with GC. From online analysis, it was found that the genetic alterations rate of SAC3D1 and its hub co-expressed genes in GC was relatively low. Therefore, it speculated that mutation and amplification may not be the main reasons for SAC3D1 to promote the development of GC. Further experimental analyses are warranted. In conclusion, the findings of the present study demonstrate that SAC3D1 is highly expressed in GC and may be associated with the progression of GC.
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![Validation of hub co-expressed genes on protein levels based on Human Protein Atlas. (A) CDK1, <https://www.proteinatlas.org/ENSG00000170312-CDK1/pathology/tissue/stomach+cancer#img>, <https://www.proteinatlas.org/ENSG00000170312-CDK1/tissue/stomach#img>; (B) CCNB1, <https://www.proteinatlas.org/ENSG00000134057-CCNB1/pathology/tissue/stomach+cancer#img>, <https://www.proteinatlas.org/ENSG00000134057-CCNB1/tissue/stomach#img>; (C) CCNB2, <https://www.proteinatlas.org/ENSG00000157456-CCNB2/pathology/tissue/stomach+cancer#img>, <https://www.protein-atlas.org/ENSG00000157456-CCNB2/tissue/stomach#img>; (D) CDC20, <https://www.proteinatlas.org/ENSG00000117399-CDC20/pathology/tissue/stomach+cancer#img>, <https://www.proteinatlas.org/ENSG00000117399-CDC20/tissue/stomach#img>. SAC3D1, SAC3 domain containing 1.](IJO-57-01-0122-g10){#f11-ijo-57-01-0122}

![Prognostic value and correlation analysis of hub co-expressed genes based on GEO and TCGA data. Prognostic meta-analysis: (A) CDK1; (B) CCNB1; (C) CCNB2; (D) CDC20. Correlation between SAC3D1 and hub co-expressed genes: (E) CDK1; (F) CCNB1; (G) CCNB2; (H) CDC20. SAC3D1, SAC3 domain containing 1.](IJO-57-01-0122-g11){#f12-ijo-57-01-0122}

###### 

SAC3D1 expression profile based on immunohistochemistry data, GEO datasets and TCGA sequencing data.

  Datasets    Country     Year   Platform           Patients   Normal    t-value   P-value                                
  ----------- ----------- ------ ------------------ ---------- --------- --------- --------- --------- --------- -------- ---------
  GSE103236   Romania     2017   GPL4133            10         10.127    0.70021   9         9.3167    0.423     -3.008   0.008
  GSE81948    Italy       2017   GPL6244            15         7.5101    0.12937   5         7.5443    0.10822   0.53     0.603
  GSE54129    China       2017   GPL570             111        6.9017    0.51905   21        6.9055    0.26462   0.05     0.96
  GSE26942    USA         2016   GPL6947            205        8.9493    0.71607   12        9.0224    0.37734   0.61     0.551
  GSE84787    China       2016   GPL17077           10         9.758     3.58558   10        9.7934    2.84105   0.024    0.981
  GSE64951    USA         2015   GPL570             63         7.6095    1.74653   31        7.1908    2.02533   -1.036   0.303
  GSE63089    China       2014   GPL5175            45         7.1186    0.52955   45        7.0702    0.53337   -0.432   0.667
  GSE56807    China       2014   GPL5175            5          7.0561    0.24711   5         6.9774    0.32808   -0.428   0.68
  GSE29272    USA         2013   GPL96              134        7.0223    0.52461   134       6.3874    0.29172   12.244   \<0.001
  GSE38940    Argentina   2012   GPL5936            34         0.0224    0.31734   31        0.0745    0.47533   0.515    0.609
  GSE33429    China       2012   GPL5175, GPL9128                                                                         
                                                    25         4.9522    0.14036   25        5.0153    0.11872   1.715    0.093
  GSE20143    India       2010   GPL9365            5          -1.0585   0.60379   2         -0.8016   0.23093   0.559    0.601
  GSE13911    Italy       2008   GPL80              38         9.3052    1.38313   31        7.1942    1.57059   -5.857   \<0.001
  GSE2685     Japan       2005   GPL571             22         7.0903    0.17473   8         7.0079    0.27967   -0.968   0.341
  GSE109476   China       2018   GPL24530           5          11.5194   0.3444    5         11.1203   0.52596   -1.42    0.194
  GSE112369   Japan       2018   GPL15207           37         9.0061    0.4449    25        8.6954    0.40925   -2.784   0.007
  GSE26899    USA         2016   GPL6947            96         9.4018    0.6073    12        9.0224    0.37734   3.0272   0.007
  GSE79973    China       2016   GPL570             8          9.3585    0.3251    9         8.5798    0.60777   3.229    0.0056
  TCGA        \-          \-     \-                 373        17.3966   0.78827   32        16.8133   0.34279   -7.984   \<0.001
  IHC         \-          \-     \-                 179        10.1899   1.93074   147       3.2381    2.77793   26.57    \<0.001

SAC3D1, SAC3 domain containing 1.

###### 

Potential of SAC3D1 to serve as a bio-marker on identifying gastric cancer tissues and normal tissue.

  Datasets    Sensitivity   Specificity   TP    FP   FN    TN
  ----------- ------------- ------------- ----- ---- ----- -----
  GSE103236   80.00%        77.80%        8     2    2     7
  GSE81948    53.33%        60.00%        8     2    7     3
  GSE54129    53.15%        61.90%        59    8    52    13
  GSE26942    51.71%        66.67%        106   4    99    8
  GSE84787    60.00%        70.00%        6     3    4     7
  GSE64951    58.73%        54.84%        37    14   26    17
  GSE63089    57.78%        55.56%        26    20   19    25
  GSE56807    80.00%        60.00%        4     2    1     3
  GSE29272    82.09%        74.63%        110   34   24    100
  GSE38940    64.71%        51.61%        22    15   12    16
  GSE33429    64.00%        64.00%        16    9    9     16
  GSE20143    80.00%        50.00%        4     1    1     1
  GSE13911    86.84%        83.87%        33    5    5     26
  GSE2685     63.64%        62.50%        14    3    8     5
  GSE109476   80.00%        80.00%        4     1    1     4
  GSE112369   62.16%        68.00%        23    8    14    17
  GSE26899    62.50%        75.00%        60    3    36    9
  GSE79973    100.00%       88.89%        8     1    0     8
  TCGA        72.39%        65.63%        270   11   103   21
  IHC         96.65%        86.39%        173   20   6     127

TP, true positive; FP, false positive; FN, false negative; TN, true negative; SAC3D1, SAC3 domain containing 1.

###### 

Association between SAC3D1 expression and some clinical pathological parameters based on immunohistochemistry data.

  Clinicopathological parameters   Group           SAC3D1 expression   t-value           P-value    
  -------------------------------- --------------- ------------------- ----------------- ---------- ----------
  Tissue                           GC tissue       179                 10.1899±1.93074              
                                   Normal tissue   147                 3.2381±2.77793    26.57      P\<0.001
  Age (years)                      ≤50             46                  10.3043±2.22979              
                                   \>50            128                 10.1484±1.83616   0.466      0.642
  Sex                              Male            128                 10.125±1.99606               
                                   Female          46                  10.3696±1.7933    0.731      0.466
  T                                T1-T2           54                  9.1111±1.9683                
                                   T3-T4           120                 10.675±1.73041    -5.029     P\<0.001
  N                                N0              65                  9.1692±1.98879               
                                   N1              87                  10.7356±1.69445              
                                   N2              22                  11.0455±1.43019   17.277     P\<0.001
  Stage                            IA-IB           38                  8.7105±1.99875               
                                   IIA-IIB         117                 10.5043±1.75491              
                                   IIIA            19                  11.2105±1.35724   18.192     P\<0.001
  Histological grade               I               28                  8.5714±2.1846                
                                   II              56                  10.25±1.77098                
                                   III             63                  10.8125±1.62202   F=15.261   P\<0.001

SAC3D1, SAC3 domain containing 1.

###### 

Association between SAC3D1 expression and some clinical pathological parameters based on TCGA data.

  Clinicopathological parameters   SAC3D1 expression   t-value           P-value   
  -------------------------------- ------------------- ----------------- --------- ---------
  Tissue                                                                           
   Non-tumor                       32                  16.8133±0.34279             
   GC                              373                 17.3966±0.78827   -7.984    \<0.001
  Sex                                                                              
   Male                            258                 17.3224±0.7312              
   Female                          143                 17.4426±0.82768   1.504     0.133
  Age (years)                                                                      
   \<60                            124                 17.3489±0.74119             
   ≥60                             273                 17.3752±0.78175   -0.316    0.752
  Grade                                                                            
   G1                              11                  17.094±1.12374              
   G2                              147                 17.3488±0.7554              
   G3                              235                 17.3891±0.76078             
   Gx                              8                   17.3374±0.72202   F=0.557   0.644
  TNM                                                                              
   T1-T1b                          25                  17.2418±0.75401             
   T2-T2b                          88                  17.3177±0.85172             
   T3                              179                 17.452±0.72991              
   T4-T4b                          105                 17.3393±0.71874   F=1.117   0.342
   N0                              121                 17.4878±0.77501             
   N1                              104                 17.3645±0.74107             
   N2                              85                  17.361±0.63662              
   N3-N3b                          74                  17.3808±0.79604             
   Nx                              16                  16.3963±0.82501   F=7.596   \<0.001
   M0                              352                 17.393±0.73777              
   M1                              27                  17.1293±1.08533             
   Mx                              22                  17.2109±0.7571    F=1.957   0.143
   I-IB                            59                  17.397±0.84514              
  Stage                                                                            
   II-IIB                          124                 17.4667±0.69269             
   III-IIIC                        156                 17.4222±0.64408             
   IV                              42                  17.2256±0.98701   F=1.142   0.332

SAC3D1, SAC3 domain containing 1.

###### 

The top 10 GO items associated with SAC3D1 and its co-expressed genes.

  Category   ID           Term                                     Count   P-value
  ---------- ------------ ---------------------------------------- ------- ----------
  BP         GO:0051301   Cell division                            69      6.42E-44
  BP         GO:0006260   DNA replication                          48      5.22E-40
  BP         GO:0007067   Mitotic nuclear division                 49      6.14E-31
  BP         GO:0000082   G1/S transition of mitotic cell cycle    33      4.98E-28
  BP         GO:0007062   Sister chromatid cohesion                32      1.46E-26
  BP         GO:0006270   DNA replication initiation               19      6.20E-22
  BP         GO:0006281   DNA repair                               35      5.10E-18
  BP         GO:0000086   G2/M transition of mitotic cell cycle    26      6.69E-16
  BP         GO:0000070   Mitotic sister chromatid segregation     14      1.42E-15
  BP         GO:0000722   Telomere maintenance via recombination   14      8.38E-14
  CC         GO:0005654   Nucleoplasm                              189     7.71E-53
  CC         GO:0005634   Nucleus                                  211     1.05E-22
  CC         GO:0000776   Kinetochore                              23      1.67E-18
  CC         GO:0000777   Condensed chromosome kinetochore         23      9.02E-18
  CC         GO:0000922   Spindle pole                             25      9.22E-18
  CC         GO:0000775   Chromosome, centromeric region           19      1.14E-16
  CC         GO:0005829   Cytosol                                  141     2.46E-16
  CC         GO:0005813   Centrosome                               41      6.89E-15
  CC         GO:0030496   Midbody                                  22      6.37E-13
  CC         GO:0005819   Spindle                                  21      1.70E-12
  MF         GO:0005515   Protein binding                          305     5.16E-29
  MF         GO:0005524   ATP binding                              80      7.62E-13
  MF         GO:0003682   Chromatin binding                        35      2.18E-11
  MF         GO:0019901   Protein kinase binding                   34      3.39E-11
  MF         GO:0043142   Single-stranded DNA-dependent                    
                          ATPase activity                          7       2.59E-08
  MF         GO:0008017   Microtubule binding                      21      6.22E-08
  MF         GO:0003677   DNA binding                              72      1.66E-07
  MF         GO:0003697   Single-stranded DNA binding              14      1.79E-07
  MF         GO:0003684   Damaged DNA binding                      11      1.44E-06
  MF         GO:0003777   Microtubule motor activity               12      1.88E-06

SAC3D1, SAC3 domain containing 1.

###### 

The 10-most KEGG pathways associated with SAC3D1 and its co-expressed genes.

  Category   ID         Term                         P-value
  ---------- ---------- ---------------------------- ----------
  KEGG       hsa04110   Cell cycle                   1.05E-31
  KEGG       hsa03030   DNA replication              2.24E-19
  KEGG       hsa00240   Pyrimidine metabolism        1.25E-08
  KEGG       hsa03430   Mismatch repair              1.01E-07
  KEGG       hsa04115   p53 signaling pathway        1.78E-06
  KEGG       hsa04114   Oocyte meiosis               1.87E-06
  KEGG       hsa03460   Fanconi anemia pathway       1.20E-05
  KEGG       hsa03410   Base excision repair         2.55E-05
  KEGG       hsa03420   Nucleotide excision repair   2.71E-04
  KEGG       hsa05203   Viral carcinogenesis         5.13E-04

SAC3D1, SAC3 domain containing 1.
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